Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer
- PMID: 17341108
- DOI: 10.1021/bc0603081
Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer
Abstract
Integrin alphavbeta3 plays a critical role in tumor angiogenesis and metastasis. Radiolabeled RGD peptides that are integrin alphavbeta3-specific are very useful for noninvasive imaging of integrin expression in rapidly growing and metastatic tumors. In this study, we determined the binding affinity of E{E[c(RGDfK)]2}2 (tetramer) and its 6-hydrazinonicotinamide conjugate (HYNIC-tetramer) against the binding of 125I-echistatin to the integrin alphavbeta3-positive MDA-MB-435 breast cancer cells. The athymic nude mice bearing MDA-MB-435 xenografts were used to evaluate the potential of ternary ligand complex [99mTc(HYNIC-tetramer)(tricine)(TPPTS)] (TPPTS = trisodium triphenylphosphine-3,3',3' '-trisulfonate) as a new radiotracer for imaging breast cancer integrin alphavbeta3 expression by single photon emission computed tomography (SPECT). It was found that the binding affinity of tetramer (IC50 = 51 +/- 11 nM) was slightly higher than that of its dimeric analogue (IC50 = 78 +/- 27 nM) and is comparable to that of the HYNIC-tetramer conjugate (IC50 = 55 +/- 11 nM) within the experimental error. Biodistribution data showed that [99mTc(HYNIC-tetramer)(tricine)(TPPTS)] had a rapid blood clearance (4.61 +/- 0.81 %ID/g at 5 min postinjection (p.i.) and 0.56 +/- 0.12 %ID/g at 120 min p.i.) and was excreted mainly via the renal route. [99mTc(HYNIC-tetramer)(tricine)(TPPTS)] had high tumor uptake with a long tumor retention (5.60 +/- 0.87 %ID/g and 7.30 +/- 1.32 %ID/g at 5 and 120 min p.i., respectively). The integrin alphavbeta3-specificity was demonstrated by co-injection of excess E[c(RGDfK)]2, which resulted in a significant reduction in tumor uptake of the radiotracer. The metabolic stability of [99mTc(HYNIC-tetramer)(tricine)(TPPTS)] was determined by analyzing urine and feces samples from the tumor-bearing mice at 120 min p.i. In the urine, about 20% of [99mTc(HYNIC-tetramer)(tricine)(TPPTS)] remained intact while only approximately 15% metabolized species was detected in feces. SPECT images displayed significant radiotracer localization in tumor with good contrast as early as 1 h p.i. The high tumor uptake and fast renal excretion make [99mTc(HYNIC-tetramer)(tricine)(TPPTS)] a promising radiotracer for noninvasive imaging of the integrin alphavbeta3-positive tumors by SPECT.
Similar articles
-
[99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.Nucl Med Biol. 2006 Nov;33(8):945-52. doi: 10.1016/j.nucmedbio.2006.09.001. Nucl Med Biol. 2006. PMID: 17127166
-
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.Mol Pharm. 2009 Jan-Feb;6(1):231-45. doi: 10.1021/mp800150r. Mol Pharm. 2009. PMID: 19067525 Free PMC article.
-
Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer.Nucl Med Biol. 2008 Jan;35(1):111-21. doi: 10.1016/j.nucmedbio.2007.08.006. Epub 2007 Nov 19. Nucl Med Biol. 2008. PMID: 18158950 Free PMC article.
-
99mTc-Hydrazinonicotinic acid-Glu-{Glu-[cyclo(Arg-Gly-Asp-D-Phe-Lys)]2}2.2007 Jul 15 [updated 2007 Aug 31]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Jul 15 [updated 2007 Aug 31]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641670 Free Books & Documents. Review.
-
99mTc-Hydrazinonicotinic acid-Glu-[cyclo(Arg-Gly-Asp-D-Phe-Lys)]2.2007 Aug 15 [updated 2007 Sep 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Aug 15 [updated 2007 Sep 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641247 Free Books & Documents. Review.
Cited by
-
Molecular imaging probes for diagnosis and therapy evaluation of breast cancer.Int J Biomed Imaging. 2013;2013:230487. doi: 10.1155/2013/230487. Epub 2013 Feb 26. Int J Biomed Imaging. 2013. PMID: 23533377 Free PMC article.
-
99mTc-Labeled Diarylpyrazoles for Single-Emission Computer Tomography Imaging of Neurotensin Receptor-Positive Tumors: A Comparative Preclinical Study.Pharmaceutics. 2025 May 27;17(6):700. doi: 10.3390/pharmaceutics17060700. Pharmaceutics. 2025. PMID: 40574013 Free PMC article.
-
Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed α v β 3 Integrin Receptors in Non-Small-Cell Lung Cancer.Contrast Media Mol Imaging. 2020 Mar 31;2020:8421657. doi: 10.1155/2020/8421657. eCollection 2020. Contrast Media Mol Imaging. 2020. PMID: 32292304 Free PMC article.
-
In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging.Am J Nucl Med Mol Imaging. 2014 Sep 6;4(6):561-70. eCollection 2014. Am J Nucl Med Mol Imaging. 2014. PMID: 25250205 Free PMC article.
-
Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.Bioconjug Chem. 2009 Dec;20(12):2199-213. doi: 10.1021/bc900167c. Bioconjug Chem. 2009. PMID: 19719118 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous